Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Ann-Sofie Jansson-Rehnberg, Christer Borgfeldt, Andreas Münch, Wilhelm Graf, Magnus Simrén, Greger Lindberg, Per M Hellström
The basic principle for treatment of idiopathic diarrhea is to delay transit through the gut in order to promote absorption of electrolytes and water. Under mild conditions bulking agents may suffice. With increasing severity, antidiarrheal pharmaceuticals may be added in a stepwise manner. Bile salt malabsorption is a clear indication for adsorptive resins, while in idiopathic diarrhea peripherally-acting opioid receptor agonists, such as loperamide, is the first-line treatment. Second-line treatment with approved indication for severe diarrhea when other treatment options fail includes opium drops...
March 22, 2023: Läkartidningen
#22
JOURNAL ARTICLE
Johann P Hreinsson, Reuben K M Wong, Jan Tack, Peter Whorwell, Marc A Benninga, Viola Andresen, Bruno Bonaz, Suck Chei Choi, Enrico S Corazziari, Javier Santos, Shin Fukudo, Motoyori Kanazawa, Xuicai Fang, Shrikant I Bangdiwala, Ami D Sperber, Olafur S Palsson, Magnus Simrén
OBJECTIVE: Many studies have been published on disorders of the gut-brain interaction (DGBI) in Asia and Western Europe, but no previous study has directly assessed the difference between the two regions. The aim was to compare the prevalence of DGBI in Asia and Western Europe. METHODS: We used data collected in a population-based Internet survey, the Rome Foundation Global Epidemiology Study, from countries in Western Europe (Belgium, France, Germany, Netherlands, Italy, Spain, Sweden, and the United Kingdom) and Asia (China, Japan, South Korea, and Singapore)...
March 24, 2023: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
#23
JOURNAL ARTICLE
Jóhann P Hreinsson, Hans Törnblom, Jan Tack, Douglas A Drossman, William E Whitehead, Shrikant I Bangdiwala, Ami D Sperber, Olafur S Palsson, Magnus Simrén
BACKGROUND & AIMS: The Rome criteria are widely accepted for diagnosing disorders of gut-brain interaction, but their global applicability has been debated. This study aimed to evaluate the validity of the Rome IV criteria by factor analysis globally, across geographical regions, by sex, and by age groups. METHODS: Data were collected in 26 countries using the Rome IV questionnaire. Forty-nine ordinal variables were used in exploratory factor analysis (EFA) to identify clusters of inter-correlated variables (factors) within the data set...
June 2023: Gastroenterology
#24
JOURNAL ARTICLE
Navkiran T Tornkvist, Ann-Sofie Backman, Marie Linder, Maria Altman, Magnus Simrén, Ola Olén, Hans Törnblom
BACKGROUND AND OBJECTIVE: National patient registers are valuable in epidemiological studies. To ensure high-quality data for studies of irritable bowel syndrome (IBS), this study aimed to validate the ICD-10 code for IBS in the Swedish National Patient Register. METHODS: The positive predictive values (PPV) for IBS defined by the Rome criteria were calculated based on a review of medical records of randomly selected individuals with a first-ever diagnostic listing of IBS in the Swedish National Patient register in the year 2005 (Rome II criteria) or 2010 (Rome III criteria)...
February 1, 2023: Scandinavian Journal of Gastroenterology
#25
JOURNAL ARTICLE
Giovanni Marasco, Cesare Cremon, Maria Raffaella Barbaro, Giulia Cacciari, Francesca Falangone, Anna Kagramanova, Dmitry Bordin, Vasile Drug, Egidia Miftode, Pietro Fusaroli, Salem Youssef Mohamed, Chiara Ricci, Massimo Bellini, Mohammed Masudur Rahman, Luigi Melcarne, Javier Santos, Beatriz Lobo, Serhat Bor, Suna Yapali, Deniz Akyol, Ferdane Pirincci Sapmaz, Yonca Yilmaz Urun, Tugce Eskazan, Altay Celebi, Huseyin Kacmaz, Berat Ebik, Hatice Cilem Binicier, Mehmet Sait Bugdayci, Munkhtsetseg Banzragch Yağcı, Husnu Pullukcu, Berrin Yalınbas Kaya, Ali Tureyen, İbrahim Hatemi, Elif Sitre Koc, Goktug Sirin, Ali Riza Calıskan, Goksel Bengi, Esra Ergun Alıs, Snezana Lukic, Meri Trajkovska, Keren Hod, Dan Dumitrascu, Antonello Pietrangelo, Elena Corradini, Magnus Simren, Jessica Sjölund, Navkiran Tornkvist, Uday C Ghoshal, Olga Kolokolnikova, Antonio Colecchia, Jordi Serra, Giovanni Maconi, Roberto De Giorgio, Silvio Danese, Piero Portincasa, Antonio Di Sabatino, Marcello Maggio, Elena Philippou, Yeong Yeh Lee, Daniele Salvi, Alessandro Venturi, Claudio Borghi, Marco Zoli, Paolo Gionchetti, Pierluigi Viale, Vincenzo Stanghellini, Giovanni Barbara
OBJECTIVES: The long-term consequences of COVID-19 infection on the gastrointestinal tract remain unclear. Here, we aimed to evaluate the prevalence of gastrointestinal symptoms and post-COVID-19 disorders of gut-brain interaction after hospitalisation for SARS-CoV-2 infection. DESIGN: GI-COVID-19 is a prospective, multicentre, controlled study. Patients with and without COVID-19 diagnosis were evaluated on hospital admission and after 1, 6 and 12 months post hospitalisation...
December 9, 2022: Gut
#26
JOURNAL ARTICLE
Luiza Moraes Holst, Cristina Iribarren, Maria Sapnara, Otto Savolainen, Hans Törnblom, Yvonne Wettergren, Hans Strid, Magnus Simrén, Maria K Magnusson, Lena Öhman
Previous in vitro studies have shown that the intestinal luminal content, including metabolites, possibly regulates epithelial layer responses to harmful stimuli and promotes disease. Therefore, we aimed to test the hypothesis that fecal supernatants from patients with colon cancer (CC), ulcerative colitis (UC) and irritable bowel syndrome (IBS) contain distinct metabolite profiles and establish their effects on Caco-2 cells and human-derived colon organoids (colonoids). The metabolite profiles of fecal supernatants were analyzed by liquid chromatography-mass spectrometry and distinguished patients with CC ( n = 6), UC ( n = 6), IBS ( n = 6) and healthy subjects ( n = 6)...
December 7, 2022: International Journal of Molecular Sciences
#27
JOURNAL ARTICLE
Magnus Simrén
No abstract text is available yet for this article.
February 2023: Nature Reviews. Gastroenterology & Hepatology
#28
RANDOMIZED CONTROLLED TRIAL
Joost P Algera, Dagsu Demir, Hans Törnblom, Sanna Nybacka, Magnus Simrén, Stine Störsrud
BACKGROUND & AIMS: Fermentable oligo-, di-, monosaccharides and polyols (FODMAPs) can provoke symptoms in patients with irritable bowel syndrome (IBS). We aimed to compare the effects of diets with low vs. moderate FODMAP content on gastrointestinal (GI) symptoms and bowel habits, and to identify possible predictors of clinical response to a low FODMAP diet and FODMAP sensitivity in IBS. METHODS: Adult participants with IBS (Rome IV criteria, n = 29) were included and adhered to two 7-day diet periods, with either low (4 g/day) or moderate (23 g/day) amounts of FODMAPs, in this randomized, double-blind, crossover study...
December 2022: Clinical Nutrition
#29
EDITORIAL
Joost P Algera, Maria K Magnusson, Lena Öhman, Stine Störsrud, Magnus Simrén, Hans Törnblom
No abstract text is available yet for this article.
December 2022: Alimentary Pharmacology & Therapeutics
#30
JOURNAL ARTICLE
Chloé Melchior, Katarina Wilpart, Irina Midenfjord, Inês A Trindade, Hans Törnblom, Jan F Tack, Magnus Simrén, Lukas Van Oudenhove
OBJECTIVE: This study aimed to investigate the associations between the different abuse types, and gastrointestinal (GI) and extraintestinal symptom severity in irritable bowel syndrome (IBS), and possible mediators of these relationships. METHODS: We assessed sexual and physical abuse in childhood and adulthood with the Drossman and Leserman abuse questionnaire, whereas GI and extraintestinal symptoms were assessed with the Gastrointestinal Symptom Rating Scale and the Symptom Check List-90 Revised...
November 2022: Psychosomatic Medicine
#31
JOURNAL ARTICLE
Axel Josefsson, Hans Törnblom, Magnus Simrén
Background/Aims: Visceral hypersensitivity is an important pathophysiologic mechanism in irritable bowel syndrome (IBS). We compared 2 barostat distension protocols and their ability to distinguish between IBS patients and healthy controls, identify subjects with rectal hypersensitivity, and their associations with gastrointestinal symptom severity. Methods: We retrospectively reviewed all patients at our unit that had undergone barostat investigations 2002-2014...
October 30, 2022: Journal of Neurogastroenterology and Motility
#32
JOURNAL ARTICLE
Joost P Algera, Esther Colomier, Chloé Melchior, Jóhann P Hreinsson, Irina Midenfjord, Egbert Clevers, Magnus Simrén, Hans Törnblom
BACKGROUND: Abnormal oroanal transit time (OATT) and visceral hypersensitivity are key pathophysiological factors in irritable bowel syndrome (IBS). The lactulose nutrient challenge test (LNCT) has been developed to assess the postprandial symptoms and gut microbial fermentation. We aimed to investigate associations between OATT, rectal sensitivity, and LNCT in IBS patients. METHODS: We included 263 IBS patients from two study cohorts, where the link between pathophysiology and symptoms was investigated...
October 11, 2022: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
#33
RANDOMIZED CONTROLLED TRIAL
Joost P Algera, Maria K Magnusson, Lena Öhman, Stine Störsrud, Magnus Simrén, Hans Törnblom
BACKGROUND: A gluten-free diet reduces symptoms in some patients with irritable bowel syndrome (IBS) through unclear mechanisms. AIMS: To assess the effects of gluten-free versus gluten-containing diet on symptoms and the gut microenvironment, and to identify predictors of response to the gluten-free diet in IBS METHODS: Twenty patients with IBS and 18 healthy controls (HC) followed a gluten-free diet during two 14-day intervention periods where they sprinkled either gluten (14 g/day) or rice flour powder over their meals...
November 2022: Alimentary Pharmacology & Therapeutics
#34
REVIEW
Michelle Bosman, Fabiënne Smeets, Sigrid Elsenbruch, Jan Tack, Magnus Simrén, Nicholas Talley, Bjorn Winkens, Ad Masclee, Daniel Keszthelyi
BACKGROUND: Pharmacological trials in functional dyspepsia (FD) are associated with high placebo response rates. We aimed to identify the magnitude and contributing factors to the placebo response. METHODS: We conducted a systematic review and meta-analysis including randomized controlled trials (RCTs) with a dichotomous outcome in adult patients with FD that compared an active pharmacotherapeutic treatment with placebo. Our main outcome was identification of the magnitude of the pooled placebo response rate for the following endpoints: symptom responder, symptom-free responder, adequate relief responder, and combined endpoint responder (i...
February 2023: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
#35
JOURNAL ARTICLE
Nikola Fritz, Sabrina Berens, Yuanjun Dong, Cristina Martínez, Stefanie Schmitteckert, Lesley A Houghton, Miriam Goebel-Stengel, Verena Wahl, Maria Kabisch, Dorothea Götze, Mauro D'Amato, Tenghao Zheng, Ralph Röth, Hubert Mönnikes, Jonas Tesarz, Felicitas Engel, Annika Gauss, Martin Raithel, Viola Andresen, Jutta Keller, Thomas Frieling, Christian Pehl, Christoph Stein-Thöringer, Gerard Clarke, Paul J Kennedy, John F Cryan, Timothy G Dinan, Eamonn M M Quigley, Robin Spiller, Caroll Beltrán, Ana María Madrid, Verónica Torres, Emeran A Mayer, Gregory Sayuk, Maria Gazouli, George Karamanolis, Mariona Bustamante, Xavier Estivil, Raquel Rabionet, Per Hoffmann, Markus M Nöthen, Stefanie Heilmann-Heimbach, Börge Schmidt, André Franke, Wolfgang Lieb, Wolfgang Herzog, Guy Boeckxstaens, Mira M Wouters, Magnus Simrén, Gudrun A Rappold, Maria Vicario, Javier Santos, Rainer Schaefert, Justo Lorenzo-Bermejo, Beate Niesler
Irritable bowel syndrome (IBS) is a gut-brain disorder of multifactorial origin. Evidence of disturbed serotonergic function in IBS accumulated for the 5-HT3 receptor family. 5-HT3 Rs are encoded by HTR3 genes and control GI function, and peristalsis and secretion, in particular. Moreover, 5-HT3 R antagonists are beneficial in the treatment of diarrhea predominant IBS (IBS-D). We previously reported on functionally relevant SNPs in HTR3A c.-42C > T (rs1062613), HTR3C p.N163K (rs6766410), and HTR3E c...
September 19, 2022: Journal of Molecular Medicine: Official Organ of the "Gesellschaft Deutscher Naturforscher und Ärzte"
#36
REVIEW
Joost P Algera, Hans Törnblom, Magnus Simrén
Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction affecting 4% of the world's population. Patients with IBS experience chronic or recurrent abdominal pain in combination with altered bowel habits (diarrhea and/or constipation), and have reduced quality of life. Despite the high prevalence and substantial burden of IBS, its pathophysiology is incompletely understood and remains to be elucidated. The importance of the gut microenvironment has been highlighted in IBS, as there are signs that the gut microbiota of patients differs from healthy controls...
October 2022: Current Opinion in Pharmacology
#37
Hannes Hagström, Magnus Simrén, Anders Ekbom
No abstract text is available yet for this article.
August 31, 2022: United European Gastroenterology Journal
#38
JOURNAL ARTICLE
I-Hsuan Huang, Jolien Schol, Rutaba Khatun, Florencia Carbone, Karen Van den Houte, Esther Colomier, Lukas Michaja Balsiger, Hans Törnblom, Tim Vanuytsel, Elias Sundelin, Magnus Simrén, Olafur S Palsson, Shrikant I Bangdiwala, Ami D Sperber, Jan Tack
BACKGROUND/OBJECTIVES: The global epidemiology of gastroparesis is unknown. The European UEG and European Society for Neurogastroenterology and motility consensus defines Gastroparesis as a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, with a symptom pattern of nausea and/or vomiting and overlapping postprandial distress syndrome (PDS). Real-world evidence of this gastroparesis-like symptom pattern is a crucial step in understanding the epidemiology of gastroparesis...
August 19, 2022: United European Gastroenterology Journal
#39
JOURNAL ARTICLE
Valeria Castro Tejera, Lena Öhman, Lars Aabakken, Bengt Fellström, Trygve Hausken, Øistein Hovde, Johann P Hreinsson, Greger Lindberg, Per Venge, Magnus Simrén, Hans Törnblom
BACKGROUND: Low-grade immune activation in the gut is a potential treatment target in irritable bowel syndrome (IBS). AIMS: To determine improvement in IBS symptoms after mesalazine treatment, and the utility of measures of immune activity in the rectal mucosa METHODS: This was a randomised, double-blind, placebo-controlled, parallel-arm, multicentre trial in subjects with IBS (Rome III criteria), with an eight-week treatment period of mesalazine 2400 mg or plcebo once-daily...
September 2022: Alimentary Pharmacology & Therapeutics
#40
JOURNAL ARTICLE
Luiza Moraes Holst, Jonas Halfvarson, Marie Carlson, Charlotte Hedin, Robert Kruse, Carl Mårten Lindqvist, Daniel Bergemalm, Sven Almér, Francesca Bresso, Maria Ling Lundström, Dirk Repsilber, Mauro D'Amato, Åsa Keita, Henrik Hjortswang, Johan Söderholm, Johanna Sundin, Hans Törnblom, Magnus Simrén, Hans Strid, Maria K Magnusson, Lena Öhman
Background: Improved mucosal immune profiling in active and quiescent colonic inflammatory bowel disease (IBD) is needed to develop therapeutic options for treating and preventing flares. This study therefore aimed to provide a comprehensive mucosal characterization with emphasis on immunological host response of patients with active ulcerative colitis (UC active), UC during remission (UC remission) and active colonic Crohn's disease (CD active). Methods: Colonic biopsies from 47 study subjects were collected for gene expression and pathway analyses using the NanoString host-response panel, including 776 genes and 56 immune-related pathways...
2022: Clinical and Experimental Gastroenterology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
